News headlines about Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Inotek Pharmaceuticals Corporation earned a news impact score of 0.09 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.7114861354556 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research analysts have issued reports on the company. Zacks Investment Research upgraded Inotek Pharmaceuticals Corporation from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Friday, July 14th. Canaccord Genuity cut Inotek Pharmaceuticals Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, HC Wainwright cut Inotek Pharmaceuticals Corporation from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a research report on Tuesday, July 11th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $3.80.
Shares of Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) opened at 2.52 on Wednesday. The stock’s 50 day moving average price is $2.09 and its 200 day moving average price is $1.63. The company’s market capitalization is $68.07 million. Inotek Pharmaceuticals Corporation has a 12-month low of $0.85 and a 12-month high of $7.95.
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.23. On average, equities research analysts forecast that Inotek Pharmaceuticals Corporation will post ($1.05) earnings per share for the current year.
Inotek Pharmaceuticals Corporation Company Profile
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.